Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.56 |
| ▸ | ITK | Q08881 | 3/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 5/20 | 0.54 |
| ▸ | BMX | P51813 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15974365 | 0.90 | EGFR (0.47) | EGFRITKJAK3BTKSYK | |
| SCHEMBL15974879 | 0.88 | EGFR (0.57) | EGFRBTKSYK | |
| SCHEMBL15974250 | 0.87 | EGFR (0.53) | EGFRITKJAK3BTKBMX | |
| SCHEMBL17388661 | 0.87 | EGFR (0.53) | EGFRITKJAK3BTKBMX | |
| SCHEMBL15973781 | 0.85 | EGFR (0.53) | EGFRITKJAK3BTKBMX | |
| SCHEMBL19665697 | 0.79 | MAPK8 (0.45) | EGFRITKJAK3BTKSYK | |
| SCHEMBL1694067 | 0.78 | JAK3 (0.44) | EGFRITKJAK3BTK | |
| SCHEMBL15974153 | 0.78 | EGFR (0.49) | EGFRITKJAK3BTKSYK | |
| SCHEMBL14060361 | 0.78 | EGFR (0.48) | EGFRITKJAK3BTKSYK | |
| SCHEMBL13859301 | 0.77 | EGFR (0.61) | EGFRITKBTKBMXSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708326-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, LLC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014130693-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | EGFR 785/4885ITK 145/4885JAK3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.